ALDX Stock Overview
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Aldeyra Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.94 |
| 52 Week High | US$11.97 |
| 52 Week Low | US$1.42 |
| Beta | 1.53 |
| 1 Month Change | 34.93% |
| 3 Month Change | 29.61% |
| 1 Year Change | -56.46% |
| 3 Year Change | -68.49% |
| 5 Year Change | -50.78% |
| Change since IPO | -45.28% |
Recent News & Updates
Recent updates
Is Aldeyra Therapeutics (NASDAQ:ALDX) Weighed On By Its Debt Load?
Feb 16
Health Check: How Prudently Does Aldeyra Therapeutics (NASDAQ:ALDX) Use Debt?
Nov 06Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?
Mar 26Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?
Nov 19Aldeyra Therapeutics on track to submit new drug application for dry eye disease treatment
Sep 14Aldeyra Therapeutics: Poised For Dry Eye Disease Therapy Monetization
Aug 04Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Debt In A Risky Way?
Aug 03Aldeyra says trial for dry eye disease candidate reached key goals
Jul 12Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?
Apr 19Aldeyra Therapeutics Stock: An Undervalued Biotech With Upcoming Catalysts
Feb 17Aldeyra Therapeutics: Tranquility's Setback Creates A Buying Opportunity If You Believe In Reproxalap
Dec 23Does Aldeyra Therapeutics (NASDAQ:ALDX) Have A Healthy Balance Sheet?
Dec 22Revisiting Aldeyra Therapeutics
Sep 29Aldeyra Therapeutics: A New Approach To Ocular Inflammatory Diseases With Impressive Clinical Data
Jun 01Aldeyra Therapeutics EPS beats by $0.01
May 06Aldeyra's conjunctivitis treatment meets late-stage study main goals
Apr 27How Many Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Shares Did Insiders Buy, In The Last Year?
Feb 23Aldeyra announces reproxalap's late-stage dry eye disease trial design
Feb 04Aldeyra initiates stock offering
Jan 13Aldeyra rated buy at Citi on reproxalap trial results
Jan 08Aldeyra's reproxalap improves dry eye disease symptoms, run-in cohort shows
Jan 07How Many Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Shares Do Institutions Own?
Jan 01
Shareholder Returns
| ALDX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.0% | 0.4% | 1.0% |
| 1Y | -56.5% | 0.9% | 21.9% |
Return vs Industry: ALDX underperformed the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: ALDX underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| ALDX volatility | |
|---|---|
| ALDX Average Weekly Movement | 11.9% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ALDX's share price has been volatile over the past 3 months.
Volatility Over Time: ALDX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 10 | Todd Brady | www.aldeyra.com |
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss.
Aldeyra Therapeutics, Inc. Fundamentals Summary
| ALDX fundamental statistics | |
|---|---|
| Market cap | US$234.09m |
| Earnings (TTM) | -US$37.54m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.2x
P/E RatioIs ALDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALDX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$37.54m |
| Earnings | -US$37.54m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.63 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 12.6% |
How did ALDX perform over the long term?
See historical performance and comparison